Clinical trials
Acute Lymphoblastic Leukemia clinical trials
Below are recruiting acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06074666Recruiting
Parent training to boost medication adherence in pediatric leukemia
This study tests a new parenting program to help improve how well children with leukemia take their oral medications at home. The program focuses on building helpful skills for giving daily medicine.
Buffalo, New YorkAges 3–9 - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Birmingham, AlabamaAges 18 years+ - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT05909059RecruitingPhase 2
CAR-T therapy for people with kidney function problems
This study tests a type of immune treatment (CAR-T) in people whose kidneys are not working well, using chemotherapy first to help the CAR-T work. It may help people with certain blood cancers who have reduced kidney function to still receive CAR-T therapy safely.
Atlanta, GeorgiaAges 18 years+ - NCT05748171RecruitingPhase 2
Testing inotuzumab for children with early ALL relapse
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
ViennaAges 1–17 - NCT05657652Recruiting
Medicine regimen for relapsed or refractory B-ALL
This trial studies a specific treatment plan (“CAV regimen”) for people with B-cell ALL that has either come back or did not respond to standard treatment. It may help control the leukemia, if you meet the health and safety requirements.
Suzhou, JiangsuAges 15–70 - NCT05366569Recruiting
CAR T-cell therapy for certain blood cancers after relapse
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
BresciaAges 18–70 - NCT05375617Recruiting
Study for newly diagnosed childhood cancers in Europe
This study follows children and teens with newly diagnosed certain leukemia (ALL) and certain favorable brain tumors to learn best care and outcomes. It may help your team compare standard treatments and monitor health over time.
New York, New YorkAges 3–21 - NCT05376111RecruitingPhase 2
Venetoclax plus azacitidine for newly diagnosed T-ALL
This Phase 2 study tests whether venetoclax combined with azacitidine can treat newly diagnosed T-ALL, a type of leukemia. It may help reduce cancer activity and improve outcomes if you meet the safety and treatment timing requirements.
Suzhou, JiangsuAges 15 years+ - NCT05289687RecruitingPhase 2
Daratumumab for hard-to-clear T-cell leukemia traces
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
Chicago, IllinoisAges 18 years+ - NCT05082519RecruitingPhase 2
Calorie restriction and exercise to improve leukemia treatment in young patients
This study tests whether a special diet (calorie restriction) and increased physical activity can make chemotherapy work better for young people with B-ALL. Participants will follow a monitored diet and exercise plan during their first month of treatment.
Los Angeles, CaliforniaAges 7–25 - NCT04794296Recruiting
Care plan for children newly diagnosed with acute lymphoblastic leukemia
This trial uses a standard treatment plan for children who have just been diagnosed with acute lymphoblastic leukemia (ALL). It aims to guide the best initial treatment for certain cell types of ALL and help improve outcomes while avoiding specific higher-risk subtypes.
AbidjanAges Up to 18 years - NCT04544592RecruitingPhase 1/Phase 2
CD19 CAR-T for children and young adults with B-cell blood cancers
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
Aurora, ColoradoAges 1 month–30 years - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Basking Ridge, New JerseyAges 18 years+ - NCT04290000Recruiting
Share samples after CAR-T treatment at Montpellier hospital
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
MontpellierAges 18 years+ - NCT04094311RecruitingPhase 3
Testing a modified cell therapy when product quality is off-spec
This study looks at using tisagenlecleucel, a cell therapy, when the final product does not meet routine “commercial release” quality standards. It focuses on whether it can still be given safely and effectively to people with serious or life-threatening illness.
Hamilton, OntarioAges birth–100 years - NCT03938987RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive aggressive lymphoma or ALL
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Calgary, AlbertaAges 2–70 - NCT03590171RecruitingPhase 2
Study for children with relapsed high-risk ALL
This Phase 2 study tests a treatment approach for children with high-risk ALL that has returned. It aims to improve outcomes after relapse by using a planned treatment schedule.
Clayton, VictoriaAges Up to 17 years - NCT03568266Recruiting
Genetic study of liver injury from a leukemia medicine
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
Los Angeles, CaliforniaAges 18 years+ - NCT07153068RecruitingPhase 1/Phase 2
SupCD7 CART therapy for CD7 positive blood cancers
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06381817RecruitingPhase 3
Stem cell transplant comparison for T-cell leukemia
This study compares two types of stem cell transplants for adults with T-ALL: one using a half-matched donor alone, and one using a half-matched donor plus umbilical cord blood. The goal is to see which approach gives better results with fewer side effects.
Suzhou, JiangsuAges Any age - NCT07677878RecruitingPhase 1
Blinatumomab and low-dose DLI after transplant for B-ALL
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
BeijingAges 18–70 - NCT06537726Recruiting
Breath test for fungal infections in leukemia patients
This trial tests if a simple breath analysis can detect invasive fungal infections early in people with acute leukemia who are undergoing chemotherapy and have a low white blood cell count. Early detection could help start treatment sooner.
Zurich, Canton of ZurichAges 18 years+ - NCT06355739Recruiting
CAR T cells for children with relapsed B-cell leukemia
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
Tianjin, Tianjin MunicipalityAges 3–18
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 384 recruiting acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.